Ethics approval and consent to participate

Mentioned in the manuscript.

Consent for publication

Not applicable.

Competing interests

L.S. received advisory boards fees from AbbVie and Janssen; educational activity AstraZeneca. DA received funding to attend symposia from Gilead and Bayer. MA received advisory boards fees from AbbVie, AstraZeneca, Janssen-Cilag; travel support from AbbVie and Novartis. RC received speaker fees from Roche, Janssen, AbbVie, AstraZeneca, Celgene, BMS, Kite, and Takeda; advisory board fees from Janssen, AbbVie, Celgene, BMS, Kite, Takeda, Incyte, Kyowa-Kirin, and ADCT; travel and accommodation expenses from Roche, Janssen, AbbVie, Celgene, BMS, Kite, Takeda, and Pfizer; research grant from Pfizer. MC received honoraria from AbbVie, Gilead, Janssen, and AstraZeneca. LS received advisory boards fees from AbbVie, BeiGene and Janssen; educational activity AstraZeneca. BE received consulting or advisory boards fees from Janssen, Roche, Novartis, AbbVie, Gilead, Celgene, ArQule, AstraZeneca, Oxford Biomedica (UK), and BeiGene; speaker / speaker’s bureau fees from Janssen, Gilead, Roche, AbbVie, Novartis, Celgene, Adaptive Biotechnologies, BioGene, and AstraZeneca; research support / research funding from Janssen, Gilead, Roche, AbbVie, BeiGene, and AstraZeneca; travel, accommodations, expenses from Janssen, Roche, Novartis, AbbVie, Gilead, and Celgene. MF received honoraria from Abbvie, Janssen, Gilead. JAG-M received honoraria for advisory board and speaker´s bureau from Mundipharma, Glaxo, AbbVie, Roche, Gilead, AstraZeneca, and Janssen; research support from Hoffman-La Roche, AbbVie, and Janssen. RG-S received educational grants from AbbVie, Janssen, and Novartis. EG received travel grants, honoraria as a consultant and/or speaker bureau for Janssen-Cilag, Roche, and AbbVie. MGDS received honoraria for consultancy/advisory boards with Roche, Janssen Cilag, Gilead, AbbVie, and BMS; research Grant from Gilead, and AstraZeneca. YH received honoraria from AbbVie, Janssen, AstraZeneca, Roche and Medison, outside the submitted work. JAH received honoraria and advisory boards fees from Janssen, AbbVie, AstraZeneca, Roche, Beigene, Gilead, and BMS-Celgene. OJ received honoraria from AbbVie, Janssen, and Roche. AK received honoraria from Janssen, BMS, Astra Zeneca, Roche/Genentech; research money from Janssen, BMS, AstraZeneca, and Roche/Genentech. SK received Travel grant from Celgene; research funding from Janssen, Roche/Genentech, and AbbVie. LL received honoraria for advisory board and lecturing from Janssen, Gilead, AbbVie, Roche, and AstraZeneca. M-DL received advisory board and travel expenses from AbbVie, Janssen, Takeda, and Roche. AG received speaker’s bureau fees from Roche, Janssen, AbbVie, Celgene, Fresenius, Novonordisk; advisory board participation fees from Janssen, and AbbVie; travel and accommodation expenses from Roche, Janssen, and AbbVie. MoMa received speaker bureau fees from Amgen, honoraria as a consultant from Gilead. JM received honoraria and travel grants from AbbVie, Janssen, Roche, Gilead, and Takeda. JAHR received honoraria and advisory boards fees from Janssen, Abbvie, AstraZeneca, Roche, Beigene, Lilly, Gilead, and BMS-Celgene. MD received honoraria from AbbVie, Janssen, Astra-Zeneca, and Novartis. FRM received research funding from Gilead; advisory board participation fees from AbbVie, Gilead, Janssen, AstraZeneca, Takeda, and Roche; speakers bureau fees from Gilead, Janssen, and AbbVie. TM received honoraria from AbbVie, Janssen, AstraZeneca, Gilead, Roche, and Alexion; advisory board participation fees from AbbVie, AstraZeneca, Janssen, Alexion, Morphosys, and Sunesis. RM received honoraria from Janssen, AbbVie, and AstraZeneca. MAP received advisory board participation fees from Janssen, AbbVie, Astra Zeneca, and Merck; speaker’s bureau fees from Janssen, AbbVie, AstraZeneca, Varifarma, and Merck. FMQ received advisory board participation fees from Astrazeneca, and Janssen; speakers bureau fees from AstraZeneca, and Janssen; consultant (but no fees) for Sandoz; travel accommodation from Amgen and Gentili. GR received consultancy fees and honoraria from Abbvie, AstraZeneca, and Janssen. MaMo received consultancy fees from Gilead srl. GMR received honoraria from AbbVie, Gilead, and Janssen; received research funding from Gilead. MS received consultancy fees, advisory board participation fees, travel grants, honoraria from Janssen, Gilead, Roche, AstraZeneca, AbbVie. MS received honoraria from AbbVie, AstraZeneca, Gilead, Janssen, and Roche. PS received funding from Gilead; advisory board participation fees from AbbVie and Janssen; honorarium AbbVie, Janssen, and AstraZeneca. SEA received speaker fees from Janssen, and Takeda. LT received advisory board participation fees from Janssen, Roche, AbbVie, Gilead, Takeda; research funding from Janssen, Roche, Takeda, and Gilead. EVDS received teaching activities fees from Amgen; speaker fees from Janssen. MV received advisory board participation fees from Janssen, Roche, Astra Zeneca, Beigene; speaker fees from Abbvie. AJ received consultancy fees from AstraZeneca, Janssen, Novartis, and Sanofi; advisory board participation fees from Astra Zeneca, Janssen, Sobi, Novartis, Sandoz, MSD, and Incyte, Beigene; speaker fees from Astra Zeneca, Janssen, Sobi, Incyte, Novartis, Abbvie, Amgen, Takeda, and Beigene. AE received honoraria and advisory boards fees from Janssen, Abbvie, Novartis, Biosidus and BMS-Celgene. AV received speaker’s bureau fees from Italfarmaco and Gilead; advisory board participation fees from Janssen and Takeda. CV received honoraria from Janssen. IM received speaker Fees from Janssen, Roche, Abbvie, Sandoz. FM received fees from Janssen, and Gilead. TW received research funding from Roche; honoraria for advisory board, and research funding from Janssen; honoraria, advisory board participation fees, and travel grant from AbbVie; speaker’s bureau fees from Gilead. TC, AK, GK, AAC, DA, MB, MBG, AC, SC, J-GC, CC-G, LDP, MRDP, GDP, CD, MD, DD, ME, MKM, LF, AF, MoF, MG, OG, YKH, TH, II, GI, OBK, EK, JLG, DL, EL, LM, RM, MaMa, MaMot, RN, JO, LO, MP, IP, VMP, GQ, RR, JGC, SS, GS, AS, OS, NS, TT, DTR, ST, MVG, EWS, MY, AR have no conflict of interest to disclose.